Corporate Member Update: Merck New Indication for Pembrolizumab

Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
 

View the complete new indication here.